| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
The target is angiotensin-converting enzyme (ACE), with IC50 = 2.6 nM for imidaprilat. Imidapril is a prodrug that is hydrolyzed by CES1 to imidaprilat, which binds ACE and inhibits the conversion of angiotensin I to angiotensin II, reducing blood pressure.
|
|---|---|
| ln Vitro |
Imidaprilat inhibits ACE with IC50 = 2.6 nM, and imidapril inhibits swine renal cortex ACE with IC50 = 9.9 μM. It also inhibits MMP-9 and has anti-inflammatory effects in monocytes.
|
| ln Vivo |
In patients, imidapril reduces blood pressure and slows progression of diabetic nephropathy. In animal models, oral imidapril reduces angiotensin II levels and blood pressure in renin-dependent hypertension.
|
| Enzyme Assay |
ACE activity is measured using purified ACE and a fluorogenic or colorimetric substrate (e.g., hippuryl-His-Leu); imidaprilat is titrated, and IC50 is derived.
|
| Cell Assay |
Plasma or cells are treated with imidapril or imidaprilat; ACE activity is measured using a fluorogenic substrate, and angiotensin II levels are quantified by ELISA.
|
| Animal Protocol |
Patients receive imidapril orally (5–20 mg daily); blood pressure, ACE activity, and angiotensin II levels are monitored. Animal studies use oral dosing with blood pressure and RAS biomarker endpoints.
|
| References | |
| Additional Infomation |
Imidapril belongs to the imidazoline class of compounds, with the chemical name (4S)-1-methyl-2-oxoimidazoline-4-carboxylic acid, where the hydrogen on the nitrogen atom of the imidazoline is replaced by (1S)-1-{[(2S)-1-ethoxy-1-oxo-4-phenylbut-2-yl]amino}ethyl. It is a prodrug of Imidapril, an angiotensin-converting enzyme inhibitor used to treat chronic heart failure. Imidapril has a dual function: antihypertensive, inhibition of peptidyl dipeptidase A (EC 3.4.15.1), and as a prodrug. It is a dipeptide, belonging to the imidazoline class of compounds, a dicarboxylic acid monoester, a secondary amino compound, an ethyl ester, and also an N-acylurea. Imidapril has been studied for the treatment of autosomal dominant polycystic kidney disease. Imidapril is an angiotensin-converting enzyme (ACE) inhibitor with antihypertensive effects. As a prodrug, iImidapril is hydrolyzed in the liver to its active form, iImidaprilat. IImidaprilat competitively binds to and inhibits the activity of ACE, thereby blocking the conversion of angiotensin I to angiotensin II. This prevents the potent vasoconstrictive effect of angiotensin II, leading to vasodilation. IImidaprilat also reduces adrenal cortex aldosterone secretion for angiotensin II, thereby increasing sodium excretion and consequently increasing water excretion.
|
| Molecular Formula |
C20H27N3O6
|
|---|---|
| Molecular Weight |
405.444885492325
|
| Exact Mass |
405.19
|
| CAS # |
89371-37-9
|
| Related CAS # |
Imidapril hydrochloride;89396-94-1
|
| PubChem CID |
5464343
|
| Appearance |
White to off-white solid powder
|
| Density |
1.266 g/cm3
|
| Boiling Point |
577ºC at 760 mmHg
|
| Melting Point |
195-197°C
|
| Flash Point |
302.8ºC
|
| LogP |
1.142
|
| tPSA |
116.25
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
7
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
29
|
| Complexity |
619
|
| Defined Atom Stereocenter Count |
3
|
| SMILES |
CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2[C@@H](CN(C2=O)C)C(=O)O
|
| InChi Key |
KLZWOWYOHUKJIG-BPUTZDHNSA-N
|
| InChi Code |
InChI=1S/C20H27N3O6/c1-4-29-19(27)15(11-10-14-8-6-5-7-9-14)21-13(2)17(24)23-16(18(25)26)12-22(3)20(23)28/h5-9,13,15-16,21H,4,10-12H2,1-3H3,(H,25,26)/t13-,15-,16-/m0/s1
|
| Chemical Name |
(4S)-3-[(2S)-2-[[(2S)-1-ethoxy-1-oxo-4-phenylbutan-2-yl]amino]propanoyl]-1-methyl-2-oxoimidazolidine-4-carboxylic acid
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: This product requires protection from light (avoid light exposure) during transportation and storage. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO: ≥ 50 mg/mL (~123.3 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 1.25 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween-80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), Clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 400 μL of PEG300 and mix well; then add 50 μL of Tween-80 and mix well; finally add 450 μL of physiological saline and adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 1.25 mg/mL (3.08 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), Clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of DMSO stock solution (12.5 mg/mL) to 900 μL of 20% SBE-β-CD saline and mix well. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.4665 mL | 12.3323 mL | 24.6646 mL | |
| 5 mM | 0.4933 mL | 2.4665 mL | 4.9329 mL | |
| 10 mM | 0.2466 mL | 1.2332 mL | 2.4665 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
